Cargando…

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Escamilla Gómez, Virginia, García-Gutiérrez, Valentín, López Corral, Lucía, García Cadenas, Irene, Pérez Martínez, Ariadna, Márquez Malaver, Francisco J., Caballero-Velázquez, Teresa, González Sierra, Pedro A., Viguria Alegría, María C., Parra Salinas, Ingrid M., Calderón Cabrera, Cristina, González Vicent, Marta, Rodríguez Torres, Nancy, Parody Porras, Rocío, Ferra Coll, Christelle, Orti, Guillermo, Valcárcel Ferreiras, David, De la Cámara LLanzá, Rafael, Molés, Paula, Velázquez-Kennedy, Kyra, João Mende, María, Caballero Barrigón, Dolores, Pérez, Estefanía, Martino Bofarull, Rodrigo, Saavedra Gerosa, Silvanna, Sierra, Jorge, Poch, Marc, Zudaire Ripa, María T., Díaz Pérez, Miguel A., Molina Angulo, Blanca, Sánchez Ortega, Isabel, Sanz Caballer, Jaime, Montoro Gómez, Juan, Espigado Tocino, Ildefonso, Pérez-Simón, José A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051903/
https://www.ncbi.nlm.nih.gov/pubmed/31700138
http://dx.doi.org/10.1038/s41409-019-0731-x
_version_ 1783502755608920064
author Escamilla Gómez, Virginia
García-Gutiérrez, Valentín
López Corral, Lucía
García Cadenas, Irene
Pérez Martínez, Ariadna
Márquez Malaver, Francisco J.
Caballero-Velázquez, Teresa
González Sierra, Pedro A.
Viguria Alegría, María C.
Parra Salinas, Ingrid M.
Calderón Cabrera, Cristina
González Vicent, Marta
Rodríguez Torres, Nancy
Parody Porras, Rocío
Ferra Coll, Christelle
Orti, Guillermo
Valcárcel Ferreiras, David
De la Cámara LLanzá, Rafael
Molés, Paula
Velázquez-Kennedy, Kyra
João Mende, María
Caballero Barrigón, Dolores
Pérez, Estefanía
Martino Bofarull, Rodrigo
Saavedra Gerosa, Silvanna
Sierra, Jorge
Poch, Marc
Zudaire Ripa, María T.
Díaz Pérez, Miguel A.
Molina Angulo, Blanca
Sánchez Ortega, Isabel
Sanz Caballer, Jaime
Montoro Gómez, Juan
Espigado Tocino, Ildefonso
Pérez-Simón, José A
author_facet Escamilla Gómez, Virginia
García-Gutiérrez, Valentín
López Corral, Lucía
García Cadenas, Irene
Pérez Martínez, Ariadna
Márquez Malaver, Francisco J.
Caballero-Velázquez, Teresa
González Sierra, Pedro A.
Viguria Alegría, María C.
Parra Salinas, Ingrid M.
Calderón Cabrera, Cristina
González Vicent, Marta
Rodríguez Torres, Nancy
Parody Porras, Rocío
Ferra Coll, Christelle
Orti, Guillermo
Valcárcel Ferreiras, David
De la Cámara LLanzá, Rafael
Molés, Paula
Velázquez-Kennedy, Kyra
João Mende, María
Caballero Barrigón, Dolores
Pérez, Estefanía
Martino Bofarull, Rodrigo
Saavedra Gerosa, Silvanna
Sierra, Jorge
Poch, Marc
Zudaire Ripa, María T.
Díaz Pérez, Miguel A.
Molina Angulo, Blanca
Sánchez Ortega, Isabel
Sanz Caballer, Jaime
Montoro Gómez, Juan
Espigado Tocino, Ildefonso
Pérez-Simón, José A
author_sort Escamilla Gómez, Virginia
collection PubMed
description Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1–5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1–10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23–67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63–89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
format Online
Article
Text
id pubmed-7051903
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70519032020-03-05 Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study Escamilla Gómez, Virginia García-Gutiérrez, Valentín López Corral, Lucía García Cadenas, Irene Pérez Martínez, Ariadna Márquez Malaver, Francisco J. Caballero-Velázquez, Teresa González Sierra, Pedro A. Viguria Alegría, María C. Parra Salinas, Ingrid M. Calderón Cabrera, Cristina González Vicent, Marta Rodríguez Torres, Nancy Parody Porras, Rocío Ferra Coll, Christelle Orti, Guillermo Valcárcel Ferreiras, David De la Cámara LLanzá, Rafael Molés, Paula Velázquez-Kennedy, Kyra João Mende, María Caballero Barrigón, Dolores Pérez, Estefanía Martino Bofarull, Rodrigo Saavedra Gerosa, Silvanna Sierra, Jorge Poch, Marc Zudaire Ripa, María T. Díaz Pérez, Miguel A. Molina Angulo, Blanca Sánchez Ortega, Isabel Sanz Caballer, Jaime Montoro Gómez, Juan Espigado Tocino, Ildefonso Pérez-Simón, José A Bone Marrow Transplant Article Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1–5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1–10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23–67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63–89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients. Nature Publishing Group UK 2019-11-07 2020 /pmc/articles/PMC7051903/ /pubmed/31700138 http://dx.doi.org/10.1038/s41409-019-0731-x Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Escamilla Gómez, Virginia
García-Gutiérrez, Valentín
López Corral, Lucía
García Cadenas, Irene
Pérez Martínez, Ariadna
Márquez Malaver, Francisco J.
Caballero-Velázquez, Teresa
González Sierra, Pedro A.
Viguria Alegría, María C.
Parra Salinas, Ingrid M.
Calderón Cabrera, Cristina
González Vicent, Marta
Rodríguez Torres, Nancy
Parody Porras, Rocío
Ferra Coll, Christelle
Orti, Guillermo
Valcárcel Ferreiras, David
De la Cámara LLanzá, Rafael
Molés, Paula
Velázquez-Kennedy, Kyra
João Mende, María
Caballero Barrigón, Dolores
Pérez, Estefanía
Martino Bofarull, Rodrigo
Saavedra Gerosa, Silvanna
Sierra, Jorge
Poch, Marc
Zudaire Ripa, María T.
Díaz Pérez, Miguel A.
Molina Angulo, Blanca
Sánchez Ortega, Isabel
Sanz Caballer, Jaime
Montoro Gómez, Juan
Espigado Tocino, Ildefonso
Pérez-Simón, José A
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
title Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
title_full Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
title_fullStr Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
title_full_unstemmed Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
title_short Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
title_sort ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051903/
https://www.ncbi.nlm.nih.gov/pubmed/31700138
http://dx.doi.org/10.1038/s41409-019-0731-x
work_keys_str_mv AT escamillagomezvirginia ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT garciagutierrezvalentin ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT lopezcorrallucia ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT garciacadenasirene ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT perezmartinezariadna ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT marquezmalaverfranciscoj ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT caballerovelazquezteresa ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT gonzalezsierrapedroa ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT viguriaalegriamariac ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT parrasalinasingridm ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT calderoncabreracristina ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT gonzalezvicentmarta ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT rodrigueztorresnancy ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT parodyporrasrocio ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT ferracollchristelle ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT ortiguillermo ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT valcarcelferreirasdavid ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT delacamarallanzarafael ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT molespaula ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT velazquezkennedykyra ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT joaomendemaria ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT caballerobarrigondolores ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT perezestefania ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT martinobofarullrodrigo ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT saavedragerosasilvanna ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT sierrajorge ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT pochmarc ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT zudaireripamariat ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT diazperezmiguela ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT molinaanguloblanca ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT sanchezortegaisabel ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT sanzcaballerjaime ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT montorogomezjuan ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT espigadotocinoildefonso ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT perezsimonjosea ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy
AT ruxolitinibinrefractoryacuteandchronicgraftversushostdiseaseamulticentersurveystudy